Postoperative outcomes of primary hepatic neuroendocrine carcinomas: review article.

Osaka city medical journal Pub Date : 2013-12-01

Hiroji Shinkawa, Satoshi Takatsuka, Ryoji Kaizaki, Yushi Fujiwara, Osamu Kurai, Osamu Yamazaki

{"title":"Postoperative outcomes of primary hepatic neuroendocrine carcinomas: review article.","authors":"Hiroji Shinkawa, Satoshi Takatsuka, Ryoji Kaizaki, Yushi Fujiwara, Osamu Kurai, Osamu Yamazaki","doi":"","DOIUrl":null,"url":null,"abstract":"Background: We examined the course of a primary hepatic neuroendocrine carcinoma (PHNEC) patient and analyzed the postoperative outcome of all reported PHNEC cases.Methods: A literature search for PHNEC cases was performed using PubMed. All reported cases and our present patient were analyzed in this study. Survival analysis was performed using the Kaplan-Meier method. Risk factors for the recurrence of PHNEC following hepatic resection were investigated.Results: A total of 43 patients were analyzed in this study. The 3-, 5-, and 7-year overall survival rates were 55%, 48%, and 48%, respectively. The 3-, 5-, and 7-year overall survival rates in surgery patients were 78% each, and 25%, 17%, and 17%, respectively in nonsurgery patients. Lymph node metastasis posed a significant risk factor for postoperative recurrence.Conclusions: Hepatic surgery is an appropriate therapeutic treatment for PHNEC without distant metastasis nor lymph node metastasis. Adjuvant chemotherapy might be necessary for PHNEC patients with lymph node metastases.","PeriodicalId":19613,"journal":{"name":"Osaka city medical journal","volume":"59 2","pages":"105-13"},"PeriodicalIF":0.0000,"publicationDate":"2013-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Osaka city medical journal","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Background: We examined the course of a primary hepatic neuroendocrine carcinoma (PHNEC) patient and analyzed the postoperative outcome of all reported PHNEC cases.

Methods: A literature search for PHNEC cases was performed using PubMed. All reported cases and our present patient were analyzed in this study. Survival analysis was performed using the Kaplan-Meier method. Risk factors for the recurrence of PHNEC following hepatic resection were investigated.

Results: A total of 43 patients were analyzed in this study. The 3-, 5-, and 7-year overall survival rates were 55%, 48%, and 48%, respectively. The 3-, 5-, and 7-year overall survival rates in surgery patients were 78% each, and 25%, 17%, and 17%, respectively in nonsurgery patients. Lymph node metastasis posed a significant risk factor for postoperative recurrence.

Conclusions: Hepatic surgery is an appropriate therapeutic treatment for PHNEC without distant metastasis nor lymph node metastasis. Adjuvant chemotherapy might be necessary for PHNEC patients with lymph node metastases.

本刊更多论文

原发性肝神经内分泌癌的术后预后:综述文章。

背景:我们检查了原发性肝神经内分泌癌(PHNEC)患者的病程，并分析了所有已报道的PHNEC病例的术后结果。方法:通过PubMed检索PHNEC病例的文献。本研究分析了所有报告病例和本例患者。采用Kaplan-Meier法进行生存分析。探讨肝切除术后PHNEC复发的危险因素。结果:本研究共分析了43例患者。3年、5年和7年的总生存率分别为55%、48%和48%。手术患者的3年、5年和7年总生存率分别为78%，非手术患者的总生存率分别为25%、17%和17%。淋巴结转移是术后复发的重要危险因素。结论:肝手术是无远处转移和淋巴结转移的PHNEC的理想治疗方法。伴有淋巴结转移的PHNEC患者可能需要辅助化疗。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Osaka city medical journal

自引率

0.00%

发文量